vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.
TransMedics Group, Inc. is the larger business by last-quarter revenue ($160.8M vs $24.8M, roughly 6.5× Ceribell, Inc.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs -54.6%, a 120.1% gap on every dollar of revenue. TransMedics Group, Inc. produced more free cash flow last quarter ($19.0M vs $-11.0M).
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
CBLL vs TMDX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $160.8M |
| Net Profit | $-13.5M | $105.4M |
| Gross Margin | 87.3% | 58.1% |
| Operating Margin | -58.9% | 13.2% |
| Net Margin | -54.6% | 65.6% |
| Revenue YoY | — | 32.2% |
| Net Profit YoY | — | 1436.9% |
| EPS (diluted) | $-0.35 | $2.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $160.8M | ||
| Q3 25 | $22.6M | $143.8M | ||
| Q2 25 | $21.2M | $157.4M | ||
| Q1 25 | $20.5M | $143.5M | ||
| Q4 24 | — | $121.6M | ||
| Q3 24 | $17.2M | $108.8M | ||
| Q2 24 | — | $114.3M | ||
| Q1 24 | — | $96.8M |
| Q4 25 | $-13.5M | $105.4M | ||
| Q3 25 | $-13.5M | $24.3M | ||
| Q2 25 | $-13.6M | $34.9M | ||
| Q1 25 | $-12.8M | $25.7M | ||
| Q4 24 | — | $6.9M | ||
| Q3 24 | $-10.4M | $4.2M | ||
| Q2 24 | — | $12.2M | ||
| Q1 24 | — | $12.2M |
| Q4 25 | 87.3% | 58.1% | ||
| Q3 25 | 88.3% | 58.8% | ||
| Q2 25 | 88.1% | 61.4% | ||
| Q1 25 | 87.9% | 61.5% | ||
| Q4 24 | — | 59.2% | ||
| Q3 24 | 87.3% | 55.9% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 61.9% |
| Q4 25 | -58.9% | 13.2% | ||
| Q3 25 | -64.8% | 16.2% | ||
| Q2 25 | -70.5% | 23.2% | ||
| Q1 25 | -69.3% | 19.1% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | -57.8% | 3.6% | ||
| Q2 24 | — | 10.9% | ||
| Q1 24 | — | 12.8% |
| Q4 25 | -54.6% | 65.6% | ||
| Q3 25 | -59.6% | 16.9% | ||
| Q2 25 | -64.4% | 22.2% | ||
| Q1 25 | -62.4% | 17.9% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | -60.6% | 3.9% | ||
| Q2 24 | — | 10.7% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | $-0.35 | $2.59 | ||
| Q3 25 | $-0.37 | $0.66 | ||
| Q2 25 | $-0.38 | $0.92 | ||
| Q1 25 | $-0.36 | $0.70 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | $-1.85 | $0.12 | ||
| Q2 24 | — | $0.35 | ||
| Q1 24 | — | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $155.3M | $473.1M |
| Total Assets | $195.8M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $177.4M | — | ||
| Q1 25 | $182.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $14.1M | $330.1M | ||
| Q2 24 | — | $362.8M | ||
| Q1 24 | — | $350.2M |
| Q4 25 | $155.3M | $473.1M | ||
| Q3 25 | $164.1M | $355.2M | ||
| Q2 25 | $172.2M | $318.1M | ||
| Q1 25 | $180.9M | $266.3M | ||
| Q4 24 | — | $228.6M | ||
| Q3 24 | $-136.0M | $209.9M | ||
| Q2 24 | — | $189.9M | ||
| Q1 24 | — | $159.5M |
| Q4 25 | $195.8M | $1.1B | ||
| Q3 25 | $199.5M | $946.0M | ||
| Q2 25 | $207.7M | $890.5M | ||
| Q1 25 | $213.5M | $837.5M | ||
| Q4 24 | — | $804.1M | ||
| Q3 24 | $47.1M | $785.6M | ||
| Q2 24 | — | $758.6M | ||
| Q1 24 | — | $723.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $34.5M |
| Free Cash FlowOCF − Capex | $-11.0M | $19.0M |
| FCF MarginFCF / Revenue | -44.2% | 11.8% |
| Capex IntensityCapex / Revenue | 0.7% | 9.7% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | $133.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $34.5M | ||
| Q3 25 | $-11.1M | $69.6M | ||
| Q2 25 | $-7.5M | $91.6M | ||
| Q1 25 | $-11.4M | $-2.9M | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | — | $6.9M | ||
| Q2 24 | — | $25.7M | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | $-11.0M | $19.0M | ||
| Q3 25 | $-11.5M | $61.9M | ||
| Q2 25 | $-7.6M | $82.5M | ||
| Q1 25 | $-11.6M | $-29.9M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $-41.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $-47.6M |
| Q4 25 | -44.2% | 11.8% | ||
| Q3 25 | -50.8% | 43.1% | ||
| Q2 25 | -35.9% | 52.4% | ||
| Q1 25 | -56.4% | -20.8% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | -38.0% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | -49.2% |
| Q4 25 | 0.7% | 9.7% | ||
| Q3 25 | 1.6% | 5.3% | ||
| Q2 25 | 0.3% | 5.8% | ||
| Q1 25 | 0.7% | 18.8% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 44.3% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
